Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as...

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Smoking is a significant risk factor for non-small-cell lung cancer (NSCLC) and bladder urothelial carcinoma (BLCA).
• A prognostic marker linking smoking-related genes to prognosis and immune checkpoint therapy efficacy is lacking for these cancers.

Purpose of the Study:

• To identify smoking-related genes in NSCLC and BLCA that predict prognosis and correlate with immune checkpoint therapy.
• To investigate the role of PRR11 as a prognostic marker and its impact on immunotherapy.
• To explore the regulatory network involving PRR11, SPDL1, and hsa-miR-200b-3p.

Main Methods:

• Differential gene expression analysis in NSCLC and BLCA.
• Prognostic model construction based on PRR11 co-expressed genes.
• Molecular docking and tissue microarray analyses to study PRR11-SPDL1 interaction.
• miRNA analysis.

Main Results:

• PRR11 identified as a crucial smoking-associated gene influencing cancer stemness and immunotherapy efficacy.
• A prognostic model based on PRR11 co-expressed genes demonstrated prognostic value in BLCA and NSCLC.
• PRR11 regulates PDL1 expression through SPDL1, impacting immunotherapeutic outcomes.
• hsa-miR-200b-3p was implicated in the PRR11-SPDL1 regulatory axis.

Conclusions:

• PRR11 is a key regulator of prognosis and immunotherapy response in smoking-related NSCLC and BLCA.
• The PRR11-SPDL1-PDL1 pathway is a critical determinant of immunotherapeutic efficacy.
• PRR11 and its associated regulatory network offer potential therapeutic targets for NSCLC and BLCA.